Dennis Podlesak - Sep 15, 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Director
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Stock symbol
SNDX
Transactions as of
Sep 15, 2022
Transactions value $
-$1,399,680
Form type
4
Date filed
9/16/2022, 05:34 PM
Previous filing
Feb 3, 2022
Next filing
Feb 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $422K +66.8K +88.22% $6.32 143K Sep 15, 2022 Direct
transaction SNDX Common Stock Sale -$1.62M -66.8K -46.87% $24.20 75.8K Sep 15, 2022 Direct F1, F2
transaction SNDX Common Stock Options Exercise $34.2K +5.42K +7.15% $6.32 81.2K Sep 16, 2022 Direct
transaction SNDX Common Stock Sale -$127K -5.42K -6.68% $23.43 75.8K Sep 16, 2022 Direct F1, F3
transaction SNDX Common Stock Options Exercise $41.6K +6.56K +8.65% $6.35 82.3K Sep 16, 2022 Direct
transaction SNDX Common Stock Sale -$154K -6.56K -7.96% $23.43 75.8K Sep 16, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -66.8K -100% $0.00* 0 Sep 15, 2022 Common Stock 66.8K $6.32 Direct F4
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -6.56K -100% $0.00* 0 Sep 16, 2022 Common Stock 6.56K $6.35 Direct F4
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -5.42K -100% $0.00* 0 Sep 16, 2022 Common Stock 5.42K $6.32 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 192,600 options to purchase shares of common stock that are vested and immediately exercisable and no unvested options to purchase shares of common stock.
F2 The sale prices ranged from $23.37 to $24.64
F3 The sale prices ranged from $22.96 to $24.07
F4 This option is fully vested.